Brief: Moberg Pharma And Bayer Sign Exclusive License Agreement For MOB-015 In Europe

Moberg Pharma AB (publ)

11/02/2019 17:08

Feb 11 (Reuters) - Moberg Pharma AB (publ)  MBPH.ST :
    * MOBERG PHARMA AND BAYER SIGN EXCLUSIVE LICENSE AGREEMENT
FOR
MOB-015 IN EUROPE
    * MOBERG PHARMA AB (PUBL)- UNDER AGREEMENT, MOBERG PHARMA IS
ELIGIBLE TO RECEIVE UP TO EUR 50 MILLION CONTINGENT ON
DEVELOPMENT AND COMMERCIAL SUCCESS
    * MOBERG PHARMA AB - BAYER WILL BE MARKETING, DISTRIBUTING,
SELLING MOB-015 IN EUROPE UPON COMPLETION OF PHASE III CLINICAL
DEVELOPMENT AND REGISTRATION
    * MOBERG PHARMA- UNDER TERMS OF LICENSE AGREEMENT, CO TO
FINALIZE
ONGOING PHASE III PROGRAM, COMPLETE REGISTRATION IN EUROPE,
PROVIDE SUPPLY FOR PRODUCT

Source text for Eikon:  ID:nWkr1gckxt 
Further company coverage:  MBPH.ST 

 ((Reuters.Briefs@thomsonreuters.com;))